Literature DB >> 17348637

Cinnamoyl compounds as simple molecules that inhibit p300 histone acetyltransferase.

Roberta Costi1, Roberto Di Santo, Marino Artico, Gaetano Miele, Paola Valentini, Ettore Novellino, Anna Cereseto.   

Abstract

Cinnamoly compounds 1a-c and 2a-d were designed, synthesized, and in vitro tested as p300 inhibitors. At different degrees, all tested compounds were proven to inactivate p300, particularly, derivative 2c was the most active inhibitor, also showing high specificity for p300 as compared to other histone acetyltransferases. Most notably, 2c showed anti-acetylase activity in mammalian cells. These compounds represent a new class of synthetic inhibitors of p300, characterized by simple chemical structures.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17348637     DOI: 10.1021/jm060943s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

Review 1.  Chemical biology of histone acetyltransferase natural compounds modulators.

Authors:  Fabrizio Dal Piaz; Antonio Vassallo; Osmany Cuesta Rubio; Sabrina Castellano; Gianluca Sbardella; Nunziatina De Tommasi
Journal:  Mol Divers       Date:  2011-01-01       Impact factor: 2.943

2.  Functional Roles of Acetylated Histone Marks at Mouse Meiotic Recombination Hot Spots.

Authors:  Irina V Getun; Zhen Wu; Mohammad Fallahi; Souad Ouizem; Qin Liu; Weimin Li; Roberta Costi; William R Roush; John L Cleveland; Philippe R J Bois
Journal:  Mol Cell Biol       Date:  2017-01-19       Impact factor: 4.272

3.  Human Trophoblast Differentiation Is Associated With Profound Gene Regulatory and Epigenetic Changes.

Authors:  Youn-Tae Kwak; Sribalasubashini Muralimanoharan; Aishwarya A Gogate; Carole R Mendelson
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

4.  Novel 3,5-bis(bromohydroxybenzylidene)piperidin-4-ones as coactivator-associated arginine methyltransferase 1 inhibitors: enzyme selectivity and cellular activity.

Authors:  Donghang Cheng; Sergio Valente; Sabrina Castellano; Gianluca Sbardella; Roberto Di Santo; Roberta Costi; Mark T Bedford; Antonello Mai
Journal:  J Med Chem       Date:  2011-06-13       Impact factor: 7.446

5.  Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.

Authors:  Fangrui Wu; Yuanda Hua; Salma Kaochar; Shenyou Nie; Yi-Lun Lin; Yuan Yao; Jingyu Wu; Xiaowei Wu; Xiaoyong Fu; Rachel Schiff; Christel M Davis; Matthew Robertson; Erik A Ehli; Cristian Coarfa; Nicholas Mitsiades; Yongcheng Song
Journal:  J Med Chem       Date:  2020-04-21       Impact factor: 7.446

6.  Disubstituted naphthyl β-D-xylopyranosides: Synthesis, GAG priming, and histone acetyltransferase (HAT) inhibition.

Authors:  Karin Thorsheim; Andrea Persson; Anna Siegbahn; Emil Tykesson; Gunilla Westergren-Thorsson; Katrin Mani; Ulf Ellervik
Journal:  Glycoconj J       Date:  2016-03-29       Impact factor: 2.916

7.  The inhibitory effects of anacardic acid on hepatitis C virus life cycle.

Authors:  Jana Hundt; Zhubing Li; Qiang Liu
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

8.  Inhibiting the HIV integration process: past, present, and the future.

Authors:  Roberto Di Santo
Journal:  J Med Chem       Date:  2013-09-25       Impact factor: 7.446

Review 9.  Targeting cancer using KAT inhibitors to mimic lethal knockouts.

Authors:  James A L Brown; Emer Bourke; Leif A Eriksson; Michael J Kerin
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

10.  Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells.

Authors:  Rossella Fioravanti; Stefano Tomassi; Elisabetta Di Bello; Annalisa Romanelli; Andrea Maria Plateroti; Rosaria Benedetti; Mariarosaria Conte; Ettore Novellino; Lucia Altucci; Sergio Valente; Antonello Mai
Journal:  Molecules       Date:  2020-07-08       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.